• Menu
  • Skip to right header navigation
  • Skip to primary navigation
  • Skip to secondary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Before Header

Call us now  07 4688 2188

  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Clifford Gouldson Lawyers

  • About
    • Our Origin Story
    • Our Manifesto
    • Our Future
    • CGLaw COVID Protocol
    • Toowoomba
    • Brisbane
    • Sunshine Coast
  • Careers
  • Community
    • 2021 Artist in Residence Program
  • Contact Us
  • Search
  • About
    • Our Origin Story
    • Our Manifesto
    • Our Future
    • CGLaw COVID Protocol
    • Toowoomba
    • Brisbane
    • Sunshine Coast
  • Careers
  • Community
    • 2021 Artist in Residence Program
  • Contact Us
  • Search

Mobile Menu

  • Our Team
  • Practice Areas
  • Knowledge
  • Events
  • Industries
  • For Individuals
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
  • Our Team
  • Practice Areas
  • Knowledge
  • Events
  • Industries
  • For Individuals

Panadol causes headache for nurofen

You are here: Home / News / Panadol causes headache for nurofen

A recent court case saw the makers of Panadol take on Nurofen in a dispute over the use of claims made during Nurofen’s advertising campaigns.

As a result, Nurofen is no longer able to advertise that its products provide faster and more effective pain relief for common headaches than Panadol because of this Federal Court of Australia decision.

The advertisements

In August 2015, Nurofen commenced a marketing campaign that essentially advised that Nurofen, which is an ibuprofen-based product, is more effective than Panadol, which contains paracetamol.

Nurofen’s campaign consisted of the following slogans:

  1. “Nurofen is better than Paracetamol for common headaches”;
  2. “Nurofen is superior to Paracetamol for tension-type headaches”; and
  3. “Nurofen is superior to Paracetamol for common headaches.”
    The slogans were printed in a wide variety of media platforms, including print advertisements in magazines and supermarket catalogues, outdoor billboard advertisements and television commercials.

The law

Section 29 of the Australian Consumer Law provides that, in essence, when a business is engaged in trade or commerce, it must not engage in misleading or deceptive conduct which would be likely to inaccurately influence the decisions of a consumer.
Panadol alleged there was no scientific basis for Nurofen’s slogans hence the litigation in the Federal Court.

The Court’s conclusion

After an extensive review of literature detailing comparative reviews of ibuprofen and paracetamol, Justice Foster found that:

  1. only one clinical trial suggested that Nurofen did provide faster and more effective pain relief for common headaches than Panadol;
  2. two other studies did not replicate the results of the one positive clinical trial; and
  3. the authors of three meta-analyses concluded that no authoritative comparison could be undertaken to compare the effects of Paracetamol and Ibuprofen with the current scientific knowledge held in this area.
    Consequently, Nurofen was found to have advertised without adequate knowledge of the truth, or otherwise, of its statements in breach of the Australian Consumer Law.

The message

Be accurate! If you are about to promote your business to the public, ensure what you say about your products or services is correct. Bending the truth may not only land you in hot water with the Australian Competition and Consumer Commission, but result in headache-causing complaints from members of the public too.

Should you need relief from such pain, please contact our Litigation + Dispute Resolution team.

Previous Post: « Ready for 1 July? We summarise the critical legal changes for businesses
Next Post: Development approval decision means extra caution for buyers »

Primary Sidebar

We can help

Harrison Humphries

Director

Brian Conrick

Senior Consultant

Michelle Kelly

Senior Associate

Agnes Derrick

Lawyer

Oliver Dornbusch

Lawyer

Alison Cassidy

Paralegal

Related Alerts

May 18, 2022
Winter is coming – and so are new duties for incorporated association board members

Changes to the Associations Incorporation Act 1981 (Act) have steadily been implemented since 2021....

May 3, 2022
Toyota Class Action Decision Applies to 264,170 Vehicles

On 7 April 2022, Justice Michael Lee of the Federal Court of Australia held that...

November 26, 2021
Stretching fabric and the truth: Lorna Jane cops $5 million in penalties

Lorna Jane claimed its activewear could stop the spread of COVID-19 after it was...

View other alerts

Footer

Clifford Gouldson Lawyers

CLIFFORD GOULDSON LAWYERS
P: 07 4688 2188
F: 07 4688 2199
mail@cglaw.com.au
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Locations

TOOWOOMBA (Head Office)
Level 1, 610 Ruthven Street,
Toowooomba Q 4350

PO Box 8208,
Toowoomba South Q 4350

Toowoomba Office

BRISBANE
Suite 1805, Level 18,
239 George Street,
Brisbane Q 4000

PO Box 12802 George Street,
Brisbane Q 4003

Brisbane Office

 

SUNSHINE COAST
L1, Regatta Corporate Building,
2 Innovation Parkway,
Birtinya Q 4575

Locked Bag 5010
Caloundra DC Q 4551

Sunshine Coast Office

Practice Areas

  • Wills, Estates, Planning + Structuring
  • Workplace
  • Litigation + Dispute Resolution
  • Commercial + Property
  • Construction
  • Intellectual Property
  • Privacy & Disclaimer
  • Terms of Use

Site Footer

CG Law (Trading) Pty Ltd ACN 143 426 028 t/a Clifford Gouldson Lawyers ABN 89 143 426 028 Liability limited by a scheme approved under professional standards legislation..

Copyright © 2022 Clifford Gouldson Lawyers · Privacy & Disclaimer · Terms of Use · Marketing by John Gray Marketing · Site by Kingfisher